Avandia F/U
Have a look at my prior post on premarketing risk evaluation. When you consider what’s happening aound Avandia (e.g. Therapeutics Daily), it puts my argument into sharp focus. Better definitions of risk from premarketing evaluations are needed for drugs like Avandia; I see no way around it. If sponsors don’t have the sense to do the necessary studies, I suppose it’ll be forced on the industry. A shame that.
